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Editorial
Gastro-oesophaGeal reflux
Gastro-oesophageal reflux (GOR) is the 
involuntary retrograde passage of gastric 
contents into the oesophagus with or without 
regurgitation. This is a common physiolog-
ical, self-limiting condition in healthy infants 
with a prevalence peaking at 3–4 months of 
age, occurring more than once a day in 50% 
of healthy infants. As infants achieve upright 
posture with neurodevelopment maturation 
and acquire a more solid diet with age, symp-
toms usually improve by 6 months old with 
resolution by 12–14 months old.1 Transient 
inappropriate relaxation of the lower oesoph-
ageal sphincter and delayed gastric emptying 
are common mechanisms leading to GOR. 
This is further exaggerated in preterm infants 
who have shorter and immature oesophagus 
with non-peristaltic motility.
how is gastro-oesophageal reflux disease 
diagnosed?
With increasingly frequency and severity, GOR 
becomes pathological. Gastro-oesophageal 
reflux disease (GORD) is defined as ‘reflux 
of gastric contents causing troublesome symp-
toms or complications or both’ by the North 
American Society for Paediatric Gastroen-
terology, Hepatology and Nutrition and the 
European Society for Paediatric Gastroen-
terology, Hepatology and Nutrition.2 Rather 
than distinct entities, GOR and GORD are 
commonly seen as a continuum and non-inva-
sive distinction of GOR and GORD is difficult. 
The term ‘troublesome symptoms’ in infants 
is vague due to the non-specific and pervasive 
nature of GOR symptoms. The lack of gold-
standard objective measures and reliance on 
symptom reporting by caregiver complicate 
the diagnostic process. Diagnosis is usually 
inferred when infants display frequent reflux 
episodes with clear association between symp-
toms and reflux without an alternate diagnosis.
ManaGeMent
The management aim of GORD should be to 
reduce symptoms and prevent complications 
without side effects. Current consensus2 
recommends expectant management with 
parental education and reassurance for 
uncomplicated GOR. Giving small frequent 
feeds is commonly used but may be imprac-
tical and may even increase the number of 
reflux episodes due to a shorter post-prandial 
time.3 Although placing infants in the prone 
or left lateral position improves GOR, this 
cannot be recommended in infants without 
cardiorespiratory monitoring due to risk of 
sudden infant death syndrome.3 There is 
also insufficient evidence to support head-up 
positioning in reducing GOR.3 Pharmaco-
logical management should be reserved for 
infants who fail to respond to conservative 
approaches.
feed thickeners
Feed thickeners are commonly used for 
managing infants with GOR despite the lack 
of strong supporting evidence.1 It is postu-
lated that feed thickener reduces GOR by 
increasing the viscosity or ‘stickiness’ of 
the liquid content, enabling the feed to be 
retained in the stomach. However, feed thick-
eners can increase the energy density and 
osmolality of the feed which may increase the 
frequency of relaxation of the lower oesoph-
ageal sphincter and delay gastric emptying, 
worsening GOR.
evidenCe
Our recent Cochrane review4 identified 
eight randomised clinical trials analysing 
the impact of feed thickener in 637 healthy 
term formula feeding infants up to 6 months 
of age with symptoms of GOR or abnormal 
oesophageal pH probe measurement. The 
trials compared feed thickened with various 
thickeners including carob bean gum, rice 
cereal, corn starch or alginate, with unthick-
ened feed, over a 1–8 weeks period. The 
trials were of variable methodological quality. 
Despite blinding of caregivers and that thick-
ened feed mainly thickens when coming 
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into contact with gastric acid, caregivers may notice 
the higher viscosity of the thickened feed both before 
feeding and after vomiting. This inevitable risk of bias 
may overestimate the improvement in reported symp-
toms by caregivers.
regurgitation
The review4 found moderate quality of evidence that 
feed thickeners reduced the number of regurgitations 
by nearly two episodes per day (mean difference (MD) 
−1.97, 95% CI −2.32 to −1.61, 6 studies 442 infants). This 
is consistent with findings from previous reviews. Infants 
given feed thickeners were also 2.5 times more likely 
to be asymptomatic from regurgitation (risk ratio 2.5, 
95% CI 1.38 to 4.51, number needed to treat 5, 2 trials in 
186 infants). However, this evidence is of low quality due 
to the small number of available trials and participants. 
The impact of feed thickeners on volume or severity of 
regurgitation was not analysed due to lack of standardisa-
tion in reporting.
non-regurgitation symptoms
The impact of feed thickeners on non-regurgitation 
symptoms was unclear with variable effects reported on 
failure to thrive, irritability and respiratory symptoms 
such as cough.
side effects
No significant side effects were identified by the review.4 
The effect of feed thickeners on diarrhoea was variable 
but trials were not powered to measure side effects and 
only reported short-term follow-up outcomes. Feed thick-
eners, especially non-standard thickeners added to feeds, 
may increase caloric density with high carbohydrate 
content. The long-term impact of providing infants with 
such high carbohydrate and low protein feed is unclear.
oesophageal ph monitoring
Oesophageal pH monitoring is an objective and sensitive 
measure of acid reflux with established normal ranges 
based on a pH cut-off value of 4. However, insensitivity 
to weak acid or non-acid reflux poses a problem in 
infants due to their milk diet which buffers gastric acid. 
Our review4 found improvement in the reflux index 
(percentage of time pH <4) by 5% in infants with feed 
thickeners (MD −5.08, 95% CI −8.89 to −1.28, 2 trials 116 
infants). This must be interpreted with caution due to 
the small number of trials analysed with previous reviews 
showing contradictory findings.
other investigations
Multiple intraluminal impedance (MII) measures the 
change in resistance caused by movement of substances 
along the oesophagus. Hence, the combination of MII 
and pH monitoring can quantify reflux regardless of pH. 
However, there is no established normal range for MII. 
These investigations may detect normal variation and 
cannot predict severity or prognosis of GOR. Invasive 
endoscopy with histology is mainly used to rule out other 
conditions rather than diagnosing GOR.2 No trials in the 
review4 reported these outcomes.
disCussion
impact on clinical practice
Feed thickeners should be considered in healthy term 
formula feeding infants with troublesome GOR. The 
reduction of nearly two episodes of regurgitation per day 
may be of clinical significance to caregivers. Currently, 
there is insufficient evidence to recommend the use of 
one form of feed thickener over the other. However, it 
is prudent to consider using feed thickeners which have 
undergone clinical evaluation.
Although alginate is commonly used in breastfeeding 
and preterm infants,1 the evidence behind this is lacking 
and its impact on breastfeeding and other side effects 
such as obesity or necrotising enterocolitis in preterm 
infants are unclear.
impact on research
Due to the self-limiting nature of GOR, adequately 
powered, randomised controlled trials with controls 
should be used to investigate the efficacy of feed thick-
ener and the balance of side effects and benefits. Future 
studies in term infants should investigate the impact 
of different types of feed thickener on GOR. Stand-
ardised reporting of symptoms such as the validated 
12-item Infant Gastro-oesophageal Reflux Questionnaire 
Revised5 should be used. Impact of feed thickeners on 
breastfeeding should also be explored.
In preterm infants, randomised trials with strict safety 
monitoring should be used. The thickened feed should 
be designed to meet the nutritional demands of preterm 
infants and started when infants tolerate full enteral 
feeds. Clinically important outcomes such as regurgi-
tation, growth and cardiorespiratory events should be 
assessed alongside objective measures such as combined 
pH and MII monitoring.
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